Atopic dermatitis (AD) is often the initial step in the ''atopic march,'' given that more than half of AD patients with moderate to severe AD develop asthma later in life. Both AD and asthma share a similar ''atopy'' phenotype that includes T helper type 2 inflammation with eosinophilia and hyper-IgE immunoglobulinemia, but the molecular mechanisms underlying the ''atopic march'' remain elusive. In the present study, we show that induced expression of thymic stromal lymphopoietin (TSLP) in mouse epidermal keratinocytes upon topical application of MC903 (a low calcemic analogue of vitamin D3) not only triggers AD as we previously reported but also aggravates experimental allergic asthma induced by ovalbumin sensitization and challenge. Our study, which provides a mouse model to study human ''atopic march,'' indicates that keratinocyte-produced TSLP may represent an important factor in the link of atopic dermatitis to asthma.
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A topic dermatitis (AD) is a common skin disease that is often associated with other atopic disorders, such as asthma and allergic rhinitis. AD, characterized by pruritic and eczematoid skin lesions, affects children (10%-20%) and adults (1%-3%) (1, 2) . Asthma is a chronic airway inflammatory disease, exhibiting lung allergic inflammation, mucus hypersecretion, and airway hyperreactivity (AHR) (3, 4) . Epidemiologic analysis shows that AD is often the initial step in the so-called ''atopic march'' (1, (5) (6) (7) , given that more than 50% of AD patients with moderate to severe AD develop asthma later in life, and the severity of AD influences the course of respiratory allergy. Both AD and asthma share an ''atopy'' phenotype that includes a T helper type 2 (Th2) inflammation with eosinophilia and hyper-IgE immunoglobulinemia (5, 6) , but the molecular mechanisms underlying the ''atopic march'' remain unclear.
Recently, thymic stromal lymphopoietin (TSLP) emerged as a likely master regulator of AD inflammation (8) (9) (10) . Overproduction of TSLP was found in keratinocytes of human AD skin lesions (11) . We reported that selective ablation of retinoid X receptors (RXRs) in epidermal keratinocytes in adult mice induces TSLP expression in epidermis and triggers an AD-like syndrome (12) . Our study (12) and a study by Yoo et al. (13) demonstrated that mice overexpressing TSLP in keratinocytes developed a similar AD-like dermatitis. More recently, we showed that topical application of MC903 (calcipotriol; a low-calcemic analogue of vitamin D3) (14) triggers an AD-like syndrome through the induction of keratinocytic TSLP expression (15, 16) . On the basis of these results, which indicate that TSLP is both sufficient and necessary in triggering an AD inflammation, and the fact that asthma is often associated with AD, we speculated that the occurrence of asthma may be increased in mice exhibiting TSLP-induced AD.
To investigate this possibility, mice topically treated with MC903 (16) were subjected to an ovalbumin (OVA)-induced asthma protocol, in which OVA sensitization and intranasal challenge induce characteristic features of allergic asthma (17) . We show here that MC903 topical treatment triggers an aggravation of OVA allergic asthma phenotype, which is mediated by MC903-induced TSLP in epidermal keratinocytes. Interestingly, the induced expression of epidermal TSLP during the OVA sensitization period was sufficient to drive an aggravation of the asthma that was generated upon OVA challenge at a time when the skin AD had resolved and no skin and blood TSLP could be detected. Our results indicate that epidermis-produced TSLP could be instrumental in the onset of the ''atopic march.''
Results

Mice Bearing MC903-Induced AD Develop Aggravated Experimental
Asthma. Wild-type BALB/c mice, topically treated with MC903 to induce AD-like dermatitis, were concomitantly subjected to an OVA experimental asthma protocol (Fig. 1A) . Upon MC903 application, both OVA-and alum (aluminum hydroxide, as control)-treated mice similarly exhibited an induction of TSLP expression in keratinocytes (16) together with a subsequent increase of serum TSLP (Fig. 1B) and developed an AD-like skin inflammation (16) (Fig. 1C and data not shown) . In contrast, ethanol (EtOH) application (as a vehicle control for MC903) induced neither TSLP expression nor an AD phenotype (16) (Fig. 1 B and C and data not shown).
To assess lung allergic inflammation, bronchoalveolar lavage (BAL) fluid was analyzed at Day (D)22. An influx of inflammatory cells was seen in BAL of OVAϩEtOH but not of alumϩEtOH mice (Fig. 1D) . Interestingly, upon MC903 application, the total BAL cell number, particularly that of eosinophils, was further increased in OVA mice but not in alum mice ( Fig. 1D ; compare OVAϩMC903 with OVAϩEtOH). Because a low amount of OVA (5 g) was used for allergen challenge, OVAϩEtOH lungs showed only mild peribronchiolar and perivascular inflammatory cell infiltration (Fig. 1E) , which was markedly increased in OVAϩMC903 lungs ( Fig. 1E and data not shown), consisting mostly of eosinophils [as shown in Fig. 1E (Insets) and confirmed by Congo red staining (Fig. 1F) ] and CD3 ϩ T lymphocytes, mainly CD4 ϩ helper T cells (Fig. 1G) . Periodic acid-Schiff (PAS) staining revealed enhanced hyperplasia of mucus-secreting goblet cells (PAS ϩ ) in medium-and large-sized bronchioles of OVAϩMC903 lungs when compared with OVAϩEtOH lungs (Fig. 1H) , whereas very few PAS ϩ cells
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were detected in airway epithelium of alumϩEtOH or alumϩMC903 mice (data not shown).
As expected, analysis of lung cytokine RNA levels showed that, compared with alum treatment, OVA treatment on its own induced the expression of Th2-type cytokines IL-4, IL-5, IL-13, and IL-6, as well as of eosinophil chemoattractant chemokines (eotaxin-1 and eotaxin-2) ( Fig. 2A ; compare OVAϩEtOH with alumϩEtOH). Upon MC903 ear application, their expression was strongly increased (Fig. 2 A; compare OVAϩMC903 with OVAϩEtOH), whereas expression of Th1 cytokines, such as IFN-␥ and TNF-␤, or of proinflammatory cytokine TNF-␣, did not change. In agreement with the report of Al-Shami et al. (18) , we did not detect any increase of TSLP RNA level in lungs of OVA mice, whereas Zhou et al. (19) found that this level was enhanced upon OVA treatment. In addition, upon MC903 treatment, there was no increase of TSLP RNA level in lungs or other tissues, except for treated skin, of both alum-and OVA-treated mice ( Fig. 2 A and ref. 16 ). Serum total IgE and OVA-specific IgE were elevated in OVAϩEtOH mice and further enhanced in OVAϩMC903 mice (Fig. 2B) . Whole-body plethysmography analyses (20) revealed that AHR to inhaled methacholine was significantly enhanced in OVAϩMC903 mice (Fig. 2C) .
Taken together, these results demonstrated that MC903 ear application not only generated local AD but also aggravated the specific allergen (i.e., OVA)-induced asthmatic phenotype. It is noteworthy that ear MC903-induced TSLP expression in keratin- (15, 23) , were subjected to the same experimental protocol (Fig. 1 A) . Upon MC903 treatment, (i) TSLP-MT mice did not develop AD-like dermatitis, (ii) there was no induction of TSLP expression (15) (Fig. 3A) , and (iii) these mice did not exhibit aggravated asthma upon OVA treatment. MC903 induced an increase of BAL total cell and eosinophil numbers in OVA-treated wild-type control (CT) mice but not in OVA-treated TSLP-MT mice (Fig. 3B) , and TSLP-MT mouse lungs failed to exhibit an aggravation of inflammatory cell infiltration (Fig. 3C ) and goblet cell hyperplasia (Fig. 3D) . Moreover, MC903-induced enhancement of lung Th2 cytokine and chemokine expression in OVA-treated CT mice (Fig. 3E) , as well as that of total IgE and OVA-specific IgE (Fig. 3F) , were all abrogated in OVA-treated TSLP-MT mice. We could not assess AHR in CT and TSLP-MT mice, because irrespective of their treatment they did not exhibit AHR in response to methacholine (data not shown), which was most probably because of the mixed genetic background (Ϸ85% C57BL/6 ϩ 15% 129/sv) (24) . Indeed, upon OVA treatment, C57BL/6 mice did not exhibit AHR to methacholine challenge (data not shown), even though other asthma-like features were aggravated upon MC903 ear topical application, including increased BAL counts, inflammatory infiltration in the lung, elevated expression of Th2 cytokines and eosinophil-attractant chemokines [ Fig. S1 A-C] , and increased production of total IgE and OVAspecific IgE (Fig. S1 D-E) , although their levels were lower as compared with BALB/c mice (Fig. 2B) . Thus, TSLP produced by keratinocytes is necessary for the aggravation of OVA-induced experimental asthma upon skin MC903 treatment. Another line of evidence further supports this conclusion. We previously demonstrated that vitamin D receptor (VDR) present in keratinocytes mediates MC903-induced TSLP expression (16): VDR epϪ/Ϫ (VDR-MT) mice in which VDR is selectively ablated in epidermal keratinocytes exhibit neither TSLP expression nor an AD-like syndrome upon MC903 treatment (Fig.  S2 A and B) . Accordingly, and similarly to TSLP-MT mice, OVAϩEtOH (n ϭ 6 mice per group). Error bars indicate SD. littermate mice] were subjected to the experimental protocol described in Fig. 1 A. (A) OVA-treated TSLP-MT mice do not develop an ear AD-like dermatitis, and their serum TSLP at D22 is not increased upon MC903 application (n ϭ 6 mice in each group). Ear sections were stained by H&E. Arrows point to dermal/epidermal junction. VDR-MT mice did not exhibit an aggravation of the asthmatic phenotype upon MC903 treatment (Fig. S2 C- 
G).
Mice with Selective Ablation of RXRs ␣ and ␤ in Keratinocytes Develop
Aggravated Airway Inflammation upon OVA Treatment. We previously reported that selective ablation of both RXRs ␣ and ␤ in adult mouse keratinocytes (RXR␣␤ epϪ/Ϫ , hereafter called RXR-MT) induced the expression of TSLP in keratinocytes and generated a spontaneous AD-like syndrome (12) . Upon OVA sensitization and challenge, RXR-MT mice developed a more severe lung inflammation, showing an increase of BAL cell counts, particularly in eosinophils (Fig. 4) , inflammatory infiltration in the lung (Fig. 4B) , hyperplasia of mucus-secreting goblet cells (Fig. 4C) , expression of Th2 cytokines and eosinophil-attractant chemokines in lungs, and production of total IgE and OVA-specific IgE (Fig. S3 A and B) . In contrast, alum-treated RXR-MT mice did not exhibit obvious lung inflammation (Fig. 4 A and B and data not shown) . These results further support that increased production of TSLP in keratinocytes, which is instrumental in triggering an AD, also aggravates an OVA-induced allergic asthma.
Increased Production of Epidermal TSLP During the OVA Sensitization
Phase Aggravates OVA-Induced Allergic Asthma. Because AD often precedes the development of asthma and allergic rhinitis (5, 7), we then examined whether restricting the expression of keratinocytic TSLP to an early time (from D Ϫ1 to D9 during the OVA sensitization phase) [OVAϩMC903(E); Fig. 5A ] could affect the OVA-induced pulmonary pathology. By D9, MC903-treated wildtype CT ears developed an AD-like skin inflammation (16) (data not shown), which weakened from D12, and ears appeared almost normal by D22. Accordingly, at D17 and D22 (before and after OVA intranasal challenge, respectively), TSLP RNA levels in MC903-treated ears returned to normal [similar to EtOH-treated ears (data not shown)], and serum TSLP could not be detected (Ͻ7.8 pg/mL). Histology showed only a minor dermal infiltrate in MC903-treated ears at D22, also indicating that skin inflammation was resolved at that time (data not shown). Interestingly, upon OVA intranasal challenge, these mice [CT OVAϩMC903(E)] still developed aggravated pulmonary inflammation, with increased cell influx in BAL, enhanced inflammatory infiltrate and Th2 cytokine expression in lungs, as well as elevated production of total IgE and OVA-specific IgE [ Fig. 5 B-E and data not shown; compare CT OVAϩMC903(E) with CT OVAϩEtOH]. Although AHR could not be assessed in these mice (on a mixed genetic background, see above), enhanced AHR to inhaled methacholine was indeed observed in wild-type BALB/c mice upon OVAϩMC903(E) treat- in lungs at D22. * P Ͻ 0.05, ** P Ͻ 0.01 (n Ն 4 mice per group). (E) Serum levels of total and OVA-specific IgE at D22. * P Ͻ 0.05, *** P Ͻ 0.001 (n Ն 4 mice per group).
Error bars indicate SD. ment, compared with OVA treatment alone (Fig. S4) . Because OVAϩMC903(E)-treated TSLP-MT mice failed to exhibit an aggravated OVA-induced lung inflammation [ Fig. 5 B-E; compare TSLP-MT OVAϩMC903(E) with CT OVAϩMC903(E)], we concluded that increased epidermal TSLP present during the allergen sensitization phase can trigger an aggravation of the asthmatic phenotype that is generated upon allergen challenge in the airway.
We next asked whether MC903-induced AD before the OVA sensitization phase would also affect OVA-induced asthma. Wildtype BALB/c mice were topically treated with MC903 every other day for 12 days to allow the development of an ear AD, and serum TSLP level reached 1030 Ϯ 370 pg/mL at D13. However, 16 days after the last MC903 treatment (D28), serum TSLP could not be detected any longer, and the dermatitis had almost disappeared (data not shown). These mice were then subjected to OVA i.p. sensitization (at D28 and D35) and intranasal challenge (at D46-D49). We found that the OVA-induced asthma did not worsen (data not shown). Thus, even though there had been a history of AD with induced epidermal TSLP, these mice did not exhibit an aggravation of lung allergic inflammation to a specific allergen (i.e., OVA), when allergen sensitization took place after AD had resolved and TSLP was not produced any longer.
Discussion
We have shown here that increased expression of TSLP in skin keratinocytes, either upon MC903 topical treatment or by ablation of RXR␣ and RXR␤ in adult mouse keratinocytes, not only locally triggers an AD but also leads to an aggravation of a concomitant OVA-induced asthma-like lung inflammation. Clearly, keratinocytic TSLP may act as an important player in the link of AD to asthma. It is noteworthy that, unlike transgenic mice overexpressing TSLP under the lung-specific SPC promoter, which develop a spontaneous lung inflammation (19) , the increased epidermal TSLP expression and subsequent increase in blood circulating TSLP in our present mouse model do not lead to any spontaneous lung inflammation in the absence of OVA sensitization and challenge ( Figs. 1 and 2 ; compare alumϩMC903 with alumϩEtOH). However, our data do not exclude that lung locally produced TSLP could be important for the development or/and maintenance of asthma, given that an increase of TSLP RNA was found in the bronchial epithelium and submucosa of asthmatic patients (25) . In this respect, we note that TSLPR Ϫ/Ϫ (TSLP receptor null) mice (18, 19) and TSLP Ϫ/Ϫ null mice (our unpublished data) fail to develop experimental asthma in response to OVA treatment, also suggesting that TSLP signaling could play an important role in allergic lung inflammation. However, it remains to be determined in which cells and at which stage TSLP and TSLPR are involved. In any event, the present results clearly show that (i) in this OVA mouse model, epidermal TSLP is dispensable for the generation of an allergic asthma, because the OVA-induced airway inflammation is similarly developed in TSLP epϪ/Ϫ (selective ablation of TSLP in epidermal keratinocytes) and wild-type CT mice [see Fig. 3 (compare CT OVAϩEtOH and TSLP-MT OVAϩEtOH), and data not shown]; (ii) although, on its own, increased expression of TSLP in keratinocytes is not sufficient in driving an asthma-like lung inflammation, it can lead to aggravation of an asthma phenotype induced by allergen sensitization and challenge.
We also found that the selective production of epidermal TSLP during the allergen sensitization phase is able to aggravate an airway allergic inflammation, even though AD has resolved and the TSLP level has returned to normal at the time of allergen challenging (Fig.  5) . Importantly, it seems that the production of epidermal TSLP enhanced the systemic immune response to the sensitizing allergen [as indicated by elevated OVA-specific IgE levels (Fig. 5E)] . Moreover, in another BALB/c mouse experiment, in which the interval between OVA sensitization and challenge was increased from 10 days (as shown in Fig. 5A ) to 50 days, we still observed an aggravation of airway inflammation and increased AHR upon overproduction of epidermal TSLP during the OVA sensitization period (data not shown), thus suggesting that TSLP can induce enhanced memory to the sensitizing allergen.
Further studies are required to uncover the cellular and molecular mechanisms underlying the effects of keratinocyte-produced TSLP on allergic asthma pathogenesis. Because increased expression of TSLP in epidermal keratinocytes is accompanied by circulating TSLP in the blood, the aggravating effect of TSLP on asthmatic lung inflammation could be mediated (i) through TSLP-TSLPR activation of immune cells that may be involved in allergic asthma pathogenesis (26, 27) , including dendritic cells (10) , T cells (28) (29) (30) , natural killer T cells (27, 31) , eosinophils (32), B cells (3, 33, 34) , and mast cells (35) , located either in lungs or in other tissues; or (ii) through other TSLP-induced factor(s) produced locally in the skin and/or systemically in AD mice. To examine the possible involvement of systemic TSLP, BALB/c mice were i.p. injected with recombinant TSLP protein every other day from D0 to D7 during OVA sensitization (Fig. 6A) , which led to a slight increase of serum TSLP level [10-20 pg/mL at D1 and D5, and undetected (Ͻ7.8 pg/mL) after D10], although no skin AD inflammation could be observed. After OVA intranasal challenge (D18 to D21), these mice developed enhanced airway inflammation, exhibiting an increase of BAL cell counts, lung inflammatory infiltrate, and total and OVA-specific IgE and lung Th2 cytokine expression (Fig. 6  B-E) , thus indicating that systemic TSLP, on its own, is sufficient to trigger the aggravation of OVA-induced asthma.
It is worth mentioning that in the present model, TSLP was induced in mouse ear skin, whereas the OVA sensitization of the experimental asthma was via i.p. injection. Because, in real life, skin is recognized as one of the initiation sites for allergen sensitizing (2), and there is evidence for a role of epicutaneous sensitization in the atopic march (36, 37) , locally increased production of TSLP in AD skin (11) could in fact enhance epicutaneous sensitization to allergens, thereby aggravating the risk to develop asthma and/or its severity, when later in life the same allergens are encountered in airways. This possibility is currently under investigation.
In conclusion, our present study not only provides a mouse model for studying possible mechanisms involved in the ''atopic march'' but also suggests that overproduction of TSLP in the skin of patients with AD could be a risk factor for the development of allergic airway inflammation. It needs to be studied clinically whether the level of TSLP in lesioned skin and/or in the serum of AD patients is predictive of subsequent occurrence and severity of asthma in these patients, and whether targeting skin TSLP expression and/or activity in AD patients could potentially help to reduce the occurrence and/or severity of allergic airway disease.
Methods
Mice. Wild-type BALB/c and C57BL/6 male mice (8 -10 weeks old) were purchased from Charles River Laboratories. Six-week-old male K14-Cre-ER T2(tg/0) /TSLP L2/L2 mice (in a mixed genetic background of Ϸ85% C57BL/6 and 15% 129/sv) (15) and K14-Cre-ER T2(tg/0) /RXR␣ L2/L2 /RXR␤ L2/L2 mice (12) (in a mixed genetic background of Ϸ50% C57BL/6 and 50% 129/sv) were i.p. injected with tamoxifen (Tam, 0.1 mg for 5 days) (23), thus yielding TSLP epϪ/Ϫ (TSLP-MT) and RXR␣␤ epϪ/Ϫ (RXR-MT) mice, respectively. Tam-injected age-and sex-matched littermates (K14-Cre-ER T2(0/0) / TSLP L2/L2 or K14-Cre-ER T2(0/0) /RXR␣ L2/L2 /RXR␤ L2/L2 mice) were used as wild-type CT mice. All mice were subjected to experiments 4 weeks after the first Tam injection. Ten-week-old male K14-Cre (tg/0) /VDR L2/L2 (in a mixed genetic background of Ϸ60% C57BL/6 and 40% 129/sv) were used as VDR epϪ/Ϫ (VDR-MT) mice (16) and their age-and sex-matched K14-Cre (0/0) /VDR L2/L2 littermates as CT mice. Breeding and maintenance of mice were performed under institutional guidelines, and all of the experimental protocols were approved by the Animal Care and Use Committee of the Institut de Gé né tique et de Biologie Molé culaire et Cellulaire.
Other Methods. MC903 topical application, OVA sensitization and challenge, TSLP administration, assessment of airway reactivity, analysis of BAL cells, histology, immunohistochemistry, serum IgE and TSLP determination, RNA analysis, and statistical analysis are described in the SI Materials and Methods.
